StockNews.com Downgrades Emergent BioSolutions (NYSE:EBS) to Hold

Emergent BioSolutions (NYSE:EBS) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Wednesday.

A number of other research firms have also recently commented on EBS. Benchmark lifted their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Emergent BioSolutions in a research report on Tuesday.

Emergent BioSolutions Stock Up 0.6 %

Shares of Emergent BioSolutions stock opened at $5.84 on Wednesday. The company has a market cap of $316.22 million, a price-to-earnings ratio of -1.42 and a beta of 1.62. Emergent BioSolutions has a twelve month low of $1.82 and a twelve month high of $15.10. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The company’s 50 day moving average is $9.38 and its 200 day moving average is $9.00.

Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.40. The business had revenue of $194.70 million for the quarter, compared to analysts’ expectations of $254.67 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. During the same quarter last year, the company posted ($0.77) EPS. Research analysts anticipate that Emergent BioSolutions will post -0.63 EPS for the current year.

Hedge Funds Weigh In On Emergent BioSolutions

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Entropy Technologies LP purchased a new stake in Emergent BioSolutions in the third quarter valued at $155,000. Landscape Capital Management L.L.C. purchased a new stake in Emergent BioSolutions in the third quarter valued at approximately $141,000. FMR LLC lifted its stake in Emergent BioSolutions by 12.6% during the third quarter. FMR LLC now owns 129,099 shares of the biopharmaceutical company’s stock worth $1,078,000 after purchasing an additional 14,446 shares in the last quarter. FORA Capital LLC acquired a new position in Emergent BioSolutions during the third quarter worth $103,000. Finally, Hilltop Holdings Inc. boosted its position in shares of Emergent BioSolutions by 7.9% during the third quarter. Hilltop Holdings Inc. now owns 171,266 shares of the biopharmaceutical company’s stock worth $1,430,000 after buying an additional 12,515 shares during the period. Institutional investors and hedge funds own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.